Oxford Biomedica (LON:OXB) Price Target Raised to GBX 380

Oxford Biomedica (LON:OXB) had its target price raised by Deutsche Bank Aktiengesellschaft from GBX 250 ($3.35) to GBX 380 ($5.09) in a research report sent to investors on Tuesday, MarketBeat reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the biopharmaceutical company’s stock.

Oxford Biomedica Trading Up 0.5 %

Shares of LON:OXB opened at GBX 381.50 ($5.11) on Tuesday. The stock has a market capitalization of £401.87 million, a price-to-earnings ratio of -234.05 and a beta of 1.09. Oxford Biomedica has a 1-year low of GBX 164.29 ($2.20) and a 1-year high of GBX 394.50 ($5.28). The company has a debt-to-equity ratio of 143.20, a quick ratio of 1.67 and a current ratio of 3.19. The company has a 50 day moving average price of GBX 349.59 and a 200 day moving average price of GBX 301.52.

About Oxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.